Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covis Pharma

http://covispharma.com

Latest From Covis Pharma

US FDA’s Drugs Center Wins Round One In Makena Dispute With Covis On Document Production

Company is not entitled to CDER's unredacted materials or predecisional drafts and emails on the proposed withdrawal of accelerated approval. However, presiding officer Celia Witten sets a 24 January deadline for CDER’s document production and requests the center re-examine what materials from a medical policy council meeting can be released.

Review Pathway Post Market Regulation & Studies

US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree

Jacqueline O’Shaughnessy takes over as acting chief scientist following Denise Hinton’s move to the surgeon general’s office; Hinton previously had been tapped by acting commissioner Janet Woodcock to make a final decision on the accelerated approval status of Covis' preterm birth prevention drug Makena.

FDA Review Pathway

AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal

Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.

Respiratory Business Strategies

Medicaid Spending On Accelerated Approvals ‘Outsized’ Relative To Use

A new study highlights a subset of high-cost drugs in Medicaid for which legal and policy tools may be available to manage spending growth.

Reimbursement Medicaid
See All

Company Information

UsernamePublicRestriction

Register